Mechanisms Behind the Disease: Understanding the Role of APRIL in IgAN Pathogenesis: A Podcast

Show notes

This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the journal's website and by using this link: https://link.springer.com/article/10.1007/s12325-026-03840-9. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access. This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Show transcript

00:00:00: You are listening to an AIDIS Journal podcast.

00:00:05: Hello, welcome to the podcast.

00:00:07: Mechanisms Behind The Disease Understanding the role of April in IgA nephropathy pathogenesis.

00:00:13: I am Dr.

00:00:14: Fumida Kamal, an aphrologist currently working at Stanford University and the Glamoural Disease Center And i'm joined here today by two experts in the field.

00:00:22: Hi!

00:00:22: I Am Dr.

00:00:23: Abdullah Jiyara, an Aphrologist specializing in Glamours disease and currently based on the universe of Pennsylvania.

00:00:29: I'm Dr.

00:00:30: Lama Abdenor, an aphrologist specialized in glomerular diseases and based at the University of California Los Angeles.

00:00:38: Thank you both!

00:00:39: I am excited for our discussion.

00:00:41: This podcast is supported by Otsuka Pharmaceutical Development & Commercialization.

00:00:45: No funding was provided to author this review To get us started.

00:00:49: Lama can give audience quick overview of IgNephropathy and how disease may manifest?

00:00:55: Of course, IgNaphropathie or IGN is a progressive immune-mediated chronic kidney disease.

00:01:02: It's also the most common primary glomerulonephritis worldwide.

00:01:07: IGNophropathy often diagnoses in adults aged twenty to forty years and patients have high burden of kidney diseases at diagnosis, with more than fifty percent of patients presenting with CKD stage three or higher.

00:01:22: The estimated annual incidence of IGNephropathy among adult patients worldwide is two point five per hundred thousand persons and within the United States it is approximately two point one per hundred thousands.

00:01:36: The incidence of IgNaphropathie varies by region and ethnicity, with male to female ratio of two point-five to one in the united states and euro compared

00:01:52: is also a heterogeneous disease in which patients can present asymptomatically or with highly variable signs and symptoms at diagnosis.

00:02:00: Proteinuria, an approximately seventy-five percent of patient, and microscopic or gross hematuria in forty to seventy percent of the patient.

00:02:09: These are among most common signs.

00:02:11: Proteinoria is an early indicator for progressive diseases while Hematuria may occur with upper respiratory or gastrointestinal infection.

00:02:20: How is IgA nephropathy usually diagnosed or classified?

00:02:24: The Goal Standard for Diagnosis of IgA Nephropathies in Kidney Biopsy.

00:02:28: For early diagnosis and treatment.

00:02:30: kidney disease improving global outcome, KDU guidelines recommend that the kidney biopsy be considered an old adult with proteinuria of zero point five gram per day or greater when IgA Nephropathy is suspected unless contraindicated.

00:02:48: Mest C score is used to evaluate key markers of kidney damage by evaluating four histologic features from a kidney biogs.

00:02:57: Misangial hypercellularity with sense for the m, endocapillary hypersellularity representing E. segmental glomerulosclerosis S and tubular atrophy interstitial fibrosis.

00:03:11: T. Mest C-scoring can help assess disease activity and severity in patients with IGNopropathy, at the risk of progression.

00:03:20: For example high M and E scores may indicate acute disease activity And be indicative of rapid disease progression while high S and T scores May indicate chronic activity and irreversible loss of kidney function.

00:03:37: What are the biggest quality of life concerns for patients with IgA nephropathy?

00:03:42: In an observational study by the UK National Registry of Rare Kidney Disease radar, most patients' IgA Nephropathies progressed to kidney failure within ten-to fifteen years of diagnosis.

00:03:53: Thirty percent of patients was proteinuria between zero point five and one gram per day And approximately twenty percent of patient was protein or less than Zero point five gram per Day Progressive to kidney Failure Within Ten Years.

00:04:06: There have also been multiple studies across different geographic regions that have shown even proteinuria levels of less than one significantly increased the risk of adverse kidney outcomes compared with lower proteinuria targets.

00:04:21: For example, in a US cohort A high urine protein to creatinine ratio was correlated with an increased risk of reaching the composite outcome.

00:04:36: In a Chinese cohort of two thousand one hundred forty-one patients with IGEN, risk of kidney failure was significantly associated with increasing proteinuria.

00:05:09: Patients with Proteinuria of zero point five to one had a five time higher risk of reaching Kidney Failure compared to patients with Proteineuria less than zero point three.

00:05:22: There is also significant mental and emotional burden for patients.

00:05:27: patients with IgA nephropathy often describe a heavy impact on their overall quality of life.

00:05:33: In one survey, of ninety-four patient approximately twenty five percent reported anxiety and approximately one in five reported depression.

00:05:41: many patients reported that they experienced social isolation upon receiving this diagnosis because A social media listening analysis reviewed, one thousand three hundred and thirty six public posts for patients.

00:05:56: And caregiver across online platform to better understand the life experience of hygiene.

00:06:03: Fatigue and pain were frequently discussed symptoms often interfering with daily activity.

00:06:09: Some post reflected fear and anxiety at diagnosis driven by limited disease understanding to emotional stress for patient and caregiver.

00:06:22: Patients highlighted the need for safe, effective treatments due to limited option and corticosteroid side effects.

00:06:30: There was also a global survey of one hundred seventeen adults with IgNephropathy.

00:06:35: Kidney disease quality-of-life theory six method is used to assess kidney specific quality life incorporating SF twelve score.

00:06:46: Patient had mean SF twelfth of forty-six point seven and forty one point nine, both lower than the scores reported for U.S.

00:06:56: general population.

00:06:57: The most burdensome patient reported symptoms were lower back pain around seventy six percent.

00:07:04: constipation seventy five percent and bone or joint pain sixty eight percent.

00:07:10: We also see the burden show up in daily functioning.

00:07:14: Among ninety seven patients surveyed Approximately one in five said their daily activities were limited, and eighty percent said they could not participate

00:07:39: of IGN treating nephrologists and eight hundred eighty-three of their patients.

00:07:49: it included participants from the United States, EU Japan and China between June and October twenty

00:07:56: one.

00:07:56: This can be very challenging for our young patients who have dreams of having a family.

00:08:01: is there any impact on them?

00:08:03: Yes unfortunately IGN also can significantly impact family planning in individuals off child bearing potential.

00:08:12: In a meta-analysis of three hundred seventy six pregnancies in two hundred seventy three women with IgN apropathy, pregnancy did not worsen long term renal function but maternal IgN Apropathy was associated with high rates of infant loss about twelve percent.

00:08:30: preterm delivery eight point five percent low birth weight.

00:08:34: About nine point five and preeclampsia.

00:08:40: While pregnancy is generally safe for women with preserved freedom function, those with stage three or higher CKD are at an increased risk of rapid EGFR decline.

00:08:50: Higher waistline proteinuria and reduced kidney function increase the risks of adverse maternal and fetal outcome.

00:08:56: Due to associated risk patients with mild-to severe CKd are advised against conception In pregnancy.

00:09:02: corticosteroids are the mainstay for IGN while neural therapy like Widesonide may be used cautiously.

00:09:09: We've spent some time now discussing what IgA nephropathy means for our patients, the impact on daily life and ongoing risk of progressive kidney function decline.

00:09:18: To understand why these clinical manifestations happen.

00:09:20: let's take a look at the biology underlying this disease.

00:09:24: Can you explain the pathophysiology of IgA Nehropathy?

00:09:27: Absolutely!

00:09:28: The pathogens of IGAN is explained by the forehead hypothesis A series of immune related events that come together to induce kidney injury.

00:09:36: HIT-I is a production of pathogenic galactose deficient IGA-I, GDI-JA-I.

00:09:42: GDIJ-I was thought to originate in the mucosa associated lymphoid tissue for instance, payer patches and tonsils where genetic predisposition and environmental factor contribute to dysregulated production.

00:09:55: HIT II as synthesis of autoantibody against GDIG A-I circulating.

00:10:00: GDIgA-I act as an auto antigen triggering production of IgA and IgG autoantibody directed against GDIGA-I.

00:10:09: The HIT-III is a formation of immune complex, GDIG-I is found almost exclusively bound to IgG and IgA antibody within these immune complexes.

00:10:20: Lastly, HIT IV is the deposition of the immune complex in the mesangium.

00:10:25: Immune complexes in the Mesangium activate the complement system driving inflammation, grescent formation.

00:10:32: Clinical manifestation of this process results in proteinuria and hematuria, ultimately resulting in worsening kidney function.

00:10:40: An understanding that this process originates within the B-cells.

00:10:43: can you walk us through how B cells contribute to the IgA nephropathy pathogenesis?

00:10:47: Yes!

00:10:54: B cells drive immune-mediated kidney injury by a few different mechanisms.

00:11:07: First, by generating aberrantly glycosylated IGA one and IgG autoantibodies that form immune complexes activate complement and modulate CD for positive T cell polarization and proliferation.

00:11:23: additionally B cells produce pro-inflammatory cytokines that activate immune cells, promote mesangial proliferation, recruit monocytes and macrophages.

00:11:34: And induce TH-seventeen differentiation.

00:11:38: B cells also can infiltrate the kidney interstitium during injury

00:11:51: of galactose deficient IGA-I containing immune complex, trigger inflammation and gluminal injury.

00:11:56: The two thousand five KDEGO guidelines emphasize both preventing and reducing these immune complexes and managing the downstream consequences of nephron

00:12:05: loss.".

00:12:06: So given how central B cells are to this process what's driving their behavior upstream?

00:12:12: Let's discuss the role April plays in B cell regulation.

00:12:20: in the tumor necrosis factor, TNF-superfamily that specifically act at later stages of B cell development compared with other cytokine involved in B cell developments such as B cell activating factor bath.

00:12:33: At mucosal surfaces antigen presenting cells such as dendritic cells capture antigen become activated and migrate to lymphoid tissue where they release cytokines such as April.

00:12:44: there naive B cells engage was antigen anti helper cells driving their activation, proliferation and differentiation to plasma cells or memory B-cells.

00:12:55: How does April contribute to abnormal IJA-I production in the formation of pathogenic immune complexes in IgA nephropathy?

00:13:03: April plays a key role in this process by preventing apoptosis of immature B-Cells and enhancing survival, proliferation & differentiation of activated B-Sells.

00:13:15: In addition... April induces antibody class switching in activated B cells and supports survival of plasma and memory B cells, resulting in sustained antibody production.

00:13:28: As a result, April promotes the production of pathogenic galactose deficient IgA-I which can lead to subsequent immune complex formation and ultimately kidney damage and loss function.

00:13:42: In a genome wide analysis study or the so-called GWAS, of more than ten thousand patients and twenty eight thousand controls.

00:13:50: A coding variant in the April gene TNFSF-III was identified as a strong genetic risk factor for IgA nephropath.

00:14:01: You mentioned earlier that April acts alongside other cytokines like BAF and B cell development.

00:14:07: what is the biological overlap between April and BAF?

00:14:10: What might be the therapeutic implications of selectively inhibiting April versus dual inhibition of April and Baph?

00:14:17: April and baph both stimulate B-cell proliferation, and are implicated in a humoral immunity and kidney disease.

00:14:24: However, April and bath act at distinct stage of B cell life cycle and clinical and preclinical data demonstrate that they have differential effect on B cell population.

00:14:34: Bath is essential for mature B cell development while April supports plasmacel survival and antibody class switching.

00:14:41: Both share the receptor tachy, but BAF uniquely binds the BAF receptor and APREL bind BCMA.

00:14:47: Innovation of BAF depletes naive and transition B cells whilst April selectively targets plasmacelles and IGA class-switching by preserving early B cells in protective

00:14:57: immunity.".

00:14:58: That's

00:14:59: right!

00:14:59: In a clinical study of patients with systemic lupus erythematosus... or SLE, about ten patients recruited and rheumatoid arthritis RA nine patient recruited.

00:15:10: April and BAF were differentially affected by B cell depleting agent RETOXIMAB.

00:15:16: following REToximab induced B cell depletion April levels decreased in SLE patients or remained unchanged in rheumatoid arthritis patients whereas BAF levels rose significantly.

00:15:32: These results suggest that BAF and APRIL are regulated differently depending on the autoimmune disease, which may influence repopulation of B cells following depletion therapies.

00:15:45: An exploratory sub-study for the Envision Trial evaluated COVID-IX severity, mucosal immunity & systemic antibody response to Covid-IX vaccination among seventy two patients with IGN aphropathy.

00:16:00: April inhibition with Sibyeprolenumab resulted in preservation of humeral and mucosal immunity to novel COVID-IX antigens following vaccination and infection.

00:16:12: In a preclinical study, selective April inhibitions protected mice from severe flu while still allowing them to mount an normal immune response While dual April and Baph inhibition impaired immunity at the level of unvaccinated mice.

00:16:27: In a POSHAC analysis of the BLIS-VII continuation study, treatment through the BAF inhibition bililumab resulted in significant reduction and circulating concentration on all B cell type and IgG level in patients' SLE.

00:16:41: Dispired reductions in B cell populations serious or severe infections were rare over six years of bilimab treatments.

00:16:48: These findings demonstrate that sustained BAF prohibition modulates B cell population overtime giving BAF's role.

00:16:56: prolonged inhibition may reduce BAF-dependent subset and subsequently impaired generation, and maintenance of memory B cells.

00:17:04: In preclinical IGN-aphropathy models, dual April and BAF inhibition broadly suppressed splenic B cells.

00:17:13: in contrast, April only inhibition had minimal effects on most B cell subsets with modest reductions in plasma blasts and plasma cells, suggesting more selective effect on Ig-class switching and plasma cell survival.

00:17:30: In a separate GDDY mouse model of IgA nephropathy, BF blockade lowered serum IgA levels but did not improve proteinuria whereas April blockade reduced both serum Ig A and proteinuria.

00:17:46: Now that we understand the immune mechanisms driving eye genophropathy, let's turn to how this translates into management.

00:17:54: The latest KDGO guidelines recommend simultaneously addressing generic drivers of nephron loss and eye-genophropathies specific drivers.

00:18:01: How does variability in disease progression shape this management strategy?

00:18:06: Patient with IGAN those kidney function both from disease specifically new mechanism such as overproduction of GDIJA-I in inflammation and from generic drivers of disease, such as hypertension and proteinuria.

00:18:18: The treatment approaches for IGNephropathy are shifting as guidelines evolve with the twenty-twenty five KDEGO Guidelines for Management of IGAN.

00:18:27: The approach for management has shifted towards earlier proactive treatment of both IGA specific and CKD related drivers.

00:18:35: Management should focus on two parallel goals reducing IJA immune complex formation and injury, addressing the longer term consequences of nephron loss.

00:18:45: The treatment goal is to reduce rate of loss-of-kidney function to less than one milliliter per minute per year... ...and maintain a UPCR of less then zero point five gram per day.

00:18:56: ideally less than zero point three gram for

00:18:58: that.".

00:18:59: How do limitations of current therapies contribute to continued disease burden & irreversible nephront loss?

00:19:06: IGA nephropathy is typically diagnosed at a stage when more than fifty percent of nephron has already been lost.

00:19:12: Nephron loss occurs early in IGAN, often before changing based on EGFRR scene.

00:19:18: Indicate and urge to diagnose and manage IGAN early.

00:19:22: although measure exists to manage the genetic response to IGA-nephropathic induced nephront loss such as using Raylian angiotensile adenosine system inhibitor RAS inhibitor or DUAL endothelin angiotensin receptor antagonist or an SGLT-II to reduce proteinuria, they do not directly address the upstream pathogenic driver of IGAN.

00:19:43: As a result many patients continue to experience underlying pathological effect despite managing

00:19:49: proteinuria.".

00:19:50: That's right!

00:19:51: Results from prospective study of ninety six patient approach studies showed that even with optimal Ras inhibition therapy Almost half of patients do not reach the proteinuria target, or less than one.

00:20:06: Despite supportive care long-term disease progression was observed in both groups In a ten year follow up of the stop IgA nephropathy trial with no significant difference in death and stage renal disease Or forty percent or greater EGFR decline between patients randomized to receive supportive care alone versus supportive care plus immunosuppression.

00:20:31: Additionally, although corticosteroids have shown benefit in patients with IGAN there is still an increased risk of adverse events.

00:20:38: The risks versus the benefits of Corticosteroid therapy may need to be evaluated in patient-to-his-IGAN.

00:20:44: Patients often need to discontinue Corticosteroid Therapy due to their increased risk for adverse effects such as infection and weight gain.

00:20:51: The testing clinical trial which evaluates efficacy on the adverse effect of CortiCosteroid in patients due to their nearly five times higher risk of serious adverse event in patients receiving corticostero.

00:21:04: In the same trial, Corticosteroid therapy initially reduced proteinuria and slowed EGFR decline but these benefits were not sustained after treatment cessation with proteinuria-increasing and EGFR declining by the thirty six months at follow up

00:21:20: period.".

00:21:23: Seventy-eight percent experience symptoms such as proteinuria and hematuria, despite optimized standard treatment.

00:21:33: And twenty six percent of patients still had more than one proteinuria after more then two years indicating ongoing risk of disease function decline.

00:21:43: a significant proportion of patients with IGNopropathy Still progress to CKD or kidney failure within decades of diagnosis.

00:21:53: This continued risk highlights that current treatment options while beneficial may be insufficient to slow down disease progression.

00:22:02: Hearing this data, it's really exciting.

00:22:05: we have newer therapies now!

00:22:06: How will the emerging understanding of April-driven pathways inform clinical management and future therapeutic development in IgA nephropathy?

00:22:15: The treatment paradigm is shifting from symptom focus management to early mechanism targeted intervention that reduce pathogenic IGA, control inflammation and protect kidney function.

00:22:26: Current clinical biomarker in IGAN like proteinuria and EGFR primarily reflect kidney damage rather than the underlying immune disease highlighting the need for emerging biomarkers such as GDIJA-I circulating immune complex and comprehensive activation markers that can better predict progression and enable earlier mechanism-targeted intervention.

00:22:49: As the role of APRIL in IGNephropathy Pathogenesis become better known, it strengthens The Mechanistic Foundation for therapies that target the underlying disease pathophysiology.

00:23:03: This opens the door to identifying patients most likely to benefit from such therapies Informing sequencing with existing therapies and accelerating development of treatment aimed to slowing down the progression of IgN-Afroquasy.

00:23:18: We still have important unanswered questions, which patients will respond best to April inhibition?

00:23:25: Can we combine April inhibitors safely with other therapies such as Neficon complement inhibitors or SGLT II inhibitors?

00:23:35: these are trials that all await.

00:23:38: Thank you, Laman Abdullah for your time today.

00:23:40: We hope to enjoy our discussion!

00:23:49: You can listen more podcasts by subscribing to AIDIS Journal Podcasts

00:23:54: with your

00:23:54: preferred podcast provider or visiting the journal website For a full list of declarations including funding and author disclosure statements and copyright information please visit article page on the journal web site.

00:24:09: The link to the article page can be found in podcast description.

New comment

Your name or nickname, will be shown publicly
At least 10 characters long
By submitting your comment you agree that the content of the field "Name or nickname" will be stored and shown publicly next to your comment. Using your real name is optional.